Antiretroviral therapy has been effective so that HIV infection is now thought of as a chronic infection rather than a deadly disease. But antiretroviral therapies do not eradicate the virus, and lifelong therapy has adverse effects and is costly. The CCBC research team is identifying cord blood grafts with engineered hematopoietic stem/progenitor cells and T cells that are naturally resistant to HIV infection for transplantation in patients with blood disorders who are infected with this virus.